1
ADIEX
Conference 'Biosimilars: lessons learned and future challenges'
On March 9, the Conference entitled 'Biosimilars: lessons learned and future challenges' was held, organized by the Foundation for the Training of the Collegiate Medical Organization and BioSim as the closing of the V edition of the online course "Biosimilars in clinical practice" directed to doctors. Several medical specialties with accumulated clinical experience in the management of biosimilar medicines were represented in the debate and presented the lessons learned and pending challenges after more than fifteen years of biosimilar medicines on the market. The conference featured a closing conference by the director of the Spanish Agency for Medicines and Health Products.
FFOMC and BioSim
https://www.youtube.com/watch?v=G_TO53vpy0w
2
medical positioning
Update on the Positioning of the Spanish Psoriasis Group (GPS) in the use of biosimilar drugs in moderate-severe Psoriasis (GPs)
Expert clinicians in the management of psoriasis at the national level sign this update of the position on the use of biosimilar drugs of the Spanish Psoriasis Group. They consider that the incorporation of biosimilar drugs in the management of moderate to severe psoriasis in our daily clinical practice has meant a revolution and repositioning of the different molecules that we use daily for its control.
The incorporation of evidence through clinical trials and experiences of real wold evidence (evidence in real life) has helped to clarify concepts and modes of use that are far from its initial position. All this makes it necessary to update the position of the psoriasis working group in the use of biosimilar drugs given the new existing reality.
Dermo-Syphiliographic Acts
https://www.sciencedirect.com/science/article/pii/S0001731023001722
3
video interview
Biosimilars in oncology. 3rd edition of ECO-interviews. Analysis of the potential of biosimilars for sustainable cancer care
The ECO Foundation for Excellence and Quality in Oncology continues, the collaboration of Pfizer, with this initiative whose objective is to disseminate topics of interest in oncology with a modern and innovative format based on a dialogue between a journalist and two specialists .
In the interview, the experience of Dr. Olga Delgado and Dr. Luis De la Cruz in their respective hospitals is offered. Topics such as the benefits for patients and society, the management and administration of biosimilars, and how to improve sustainability and access to innovative drugs are addressed.
ECO Foundation
https://farmacosalud.com/biosimilares-en-oncologia-3a-edicion-de-eco-interviews/
4
Article
Multiple Sclerosis Treatments. Biologicals, biosimilars and generics: everything you need to know
Multiple Sclerosis Spain (EME) is a space for meeting, exchange and continuous learning for people with Multiple Sclerosis (MS) and their environment, organizations of people with MS, social and health professionals, scientists, donors, volunteers and collaborators. Among other tasks, it contributes to information about this disease, its treatments, etc. Thus, EME, given the imminent arrival of monoclonal antibody biosimilars for the treatment of MS, includes in this article the contribution of biosimilars to the efficient use of resources and the sustainability of the health system and encourages people with MS to know better biosimilar and generic treatments, the differences between them and the associated legal regulations, if any type of change in their treatment is proposed or occurs, among others.
Multiple Sclerosis Spain
https://esclerosismultiple.com/tratamientos_esclerosis_multiple_biologicos_biosimilares_genericos/
5
Guide
What is a biosimilar medicine
The English NHS has recently updated its section What is a biosimilar medicine. The objective has been to adapt the previous version to the recent regulatory developments of the MHRA and the position of EMA-HMA on interchangeability to which they refer. The document, beyond basic regulatory concepts, goes one step further by literally expressing that biosimilars should be used since they improve the cost-effectiveness ratio, thus contributing to earlier access for patients to therapies.
National Health Service England
https://www.england.nhs.uk/long-read/what-is-a-biosimilar-medicine/